Paoletti_edit.qxp 8/2/08 10:19 Page 51
Cardiovascular Risk in Patients with Chronic Kidney Disease
who responded to combined therapy with ACE inhibitors and epoetin with following successful renal transplantation. This picture probably reflects
a regression of LVH showed a greater survival rate in long-term follow-up the synergistic action of ‘traditional risk factors’ whose expression is
than subjects with persisting LVH.
Similar behaviour was shown for heart increased in renal disease, and emerging factors that are specific to CKD
disease (HD) patients with concentric LVH, who responded with an LVH and particularly to ESRD. An early multifactorial intervention aimed at
regression to a prolonged course of ACE inhibitors, and whose long-term controlling arterial hypertension, anaemia, Ca-P metabolism
incidence of non-fatal CV events was lower than that of eccentric LVH
patients unresponsive to such a treatment.
The risk of unfavourable cardiovascular
A reduction of the risk of CV death at five years was observed in renal
prognosis increases as renal insufficiency
transplant recipients on cyclosporine undergoing active treatment of
dyslipidaemia with fluvastatine compared with placebo.
progresses towards end-stage renal
recent retrospective analysis of more than 2,000 renal transplant
disease (ESRD), reaches its maximum in
recipients in Austria showed a better survival rate for patients who had
undergone renin-angiotensin blockade with either ACE inhibitors or
ESRD and persists following successful
angiotenin receptor blocker (ARB),
although a more recent analogous
retrospective analysis evaluating data from the European Transplant
Registry did not confirm this observation in a larger population sample.
abnormalities and all of the putative risk factors involved in the high
Conclusions prevalence of CVD of renal patients should be the most advisable
The risk of unfavourable CV prognosis increases as renal insufficiency strategy for offsetting this dismal situation and improving the general
progresses towards ESRD, reaches its maximum in ESRD and persists and CV prognosis of patients suffering from renal disease. ■
1. Levey AS, Controlling the epidemic of cardiovascular disease cardiovascular disease in chronic renal disease, Am J Kidney Dis, Nephrol, 2000;11:1735–43.
in chronic renal disease: where do we start?, Am J Kidney Dis, 1998;32(Suppl. 3):S112–S119. 30. Rigatto C, Parfrey P, Foley RN, et al., Congestive heart failure
1998;32(Suppl. 3):S5-S13. 16. Parfrey PS, Foley RN, Harnett JD, et al., Outcome and risk in renal transplant recipients: risk factors, outcomes and
2. Ruilope LM, Salvetti A, Jamerson K, et al., Renal function and factors for left ventricular disorders in chronic uraemia, Nephrol relationship with ischemic heart disease, J Am Soc Nephrol,
intensive lowering of blood pressure in hypertensive Dial Transplant, 1996;11:1277–85. 2002;13:1084–90.
participants of the hypertension optimal treatment (HOT) 17. Zoccali C, Benedetto FA, Mallamaci F, et al., Left ventricular 31. Rigatto C, Foley RN, Jeffery J, et al., Electrocardiographic left
study, J Am Soc Nephrol, 2001;12:218–25. mass monitoring in the follow-up of dialysis patients: ventricular hypertrophy in renal transplant recipients:
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and prognostic value of left ventricular hypertrophy progression, prognostic value and impact of blood pressure and anemia, J
the risks of death, cardiovascular events, and hospitalisations, Kidney Int, 2004;65:1492–8. Am Soc Nephrol, 2003;14:462–8.
N Engl J Med, 2004;351:1296–1305. 18. Paoletti E, Specchia C, Di Maio G, et al., The worsening of left 32. Lewis EJ, Hunsicker LG, Clarke WR, et al., Renoprotective
4. Keith DS, Nichols GA, Gullion GM, et al., Longitudinal follow- ventricular hypertrophy is the strongest predictor of sudden effect of the angiotensin-receptor antagonist irbesartan in
up and outcomes among a population with chronic kidney cardiac death in haemodialysis patients: a 10-year survey, patients with nephropathy due to type 2 diabetes, N Engl J Med,
disease in a large managed care organization, Arch Intern Med, Nephrol Dial Transplant, 2004;19:1829–34. 2001;345:851–60.
2004;164:659–63. 19. Foley RN, Parfrey PS, Harnett JD, et al., Impact of 33. Berl T, Hunsicker LG, Lewis GB, et al., for the Collaborative
5. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular hypertension on cardiomyopathy, morbidity and mortality in Study Group, Impact of achieved blood pressure on
disease and mortality in a community-based cohort with mild end-stage renal disease, Kidney Int, 1996;49:1379–85. cardiovascular outcomes in the Irbesartan Diabetic
renal insufficiency, Kidney Int, 1999;56:14–19. 20. Paoletti E, Cannella G, Update on erythropoietin treatment: Nephropathy Trial, J Am Soc Nephrol, 2005;16:2170–79.
6. De Nicola L, Minutolo R, Chiodini P, et al., Global approach to should haemoglobin be normalised in patients with chronic 34. Mann JF, Gerstein HC, Pogue J, et al., Renal insufficiency as a
cardiovascular risk in chronic kidney disease: reality and kidney disease?, J Am Soc Nephrol, 2006;17(Suppl. 2):S74–S77. predictor of cardiovascular outcomes and the impact of
opportunities for intervention, Kidney Int, 2006;69:538–45 21. Clinical practice guidelines and clinical practice ramipril: the HOPE randomized trial, Ann Intern Med,
7. Buckalew VM, Berg RL, Wang SR, et al., the Modification of recommendations for anemia in chronic kidney disease in 2001;134:629–36.
Diet in Renal Disease Study Group. Prevalence of hypertension adults, Am J Kidney Dis, 2006;47:16–85. 35. de Zeeuw D, Remuzzi G, Parving HH, et al., Albuminuria, a
in 1795 subjects with chronic renal disease: the Modification 22. Ofsthun N, LaBrecque J, Lacson E, et al., The effects of higher therapeutic target for cardiovascular protection in type 2
of Diet in Renal Disease Study baseline cohort, Am J Kidney Dis, haemoglobin levels on mortality and hospitalization in diabetic patients with nephropathy, Circulation, 2004;111:
1996;28:811–21. haemodialysis patients, Kidney Int, 2003;63:1908–14. 921–7.
8. Andersen MJ, Khawandi W, Agarwal R, Home blood pressure 23. Raggi P, Boulay A, Chasan-Taber S, et al., Cardiac 36. London GM, Pannier B, Guerin AP, et al., Alterations of left
monitoring in CKD, Am J Kidney Dis, 2005:45:994–1001. calcification in adult hemodialysis patients. A link between ventricular hypertrophy in and survival of patients receiving
9. Paoletti E, Bellino D, Amidone M, et al., Relationship between end-stage renal disease and cardiovascular disease?, J Am Coll hemodialysis: follow-up of an interventional study, J Am Soc
arterial hypertension and renal damage in chronic kidney Cardiol, 2002;39:695–701. Nephrol, 2001;12:2759–67.
disease: insights from ABPM, J Nephrol, 2006;19:778–82. 24. Block GA, Klassen PS, Lazarus JM, et al., Mineral metabolism, 37. Paoletti E, Cassottana P, Bellino D, et al., Left ventricular
10. Levin A, Singer J, Thompson CR, et al., Prevalent left mortality, and morbidity in maintenance haemodialysis, J Am geometry and adverse cardiovascular events in chronic
ventricular hypertrophy in pre-dialysis population: identifying Soc Nephrol, 2004;15:2208–18. hemodialysis patients on prolonged therapy with Ace
opportunities for intervention, Am J Kidney Dis, 25. Zoccali C, Bode-Boger S, Mallamaci F, et al., Plasma inhibitors, Am J Kidney Dis, 2002;40:728–36.
1996;27:347–54. concentration of asymmetrical dimethylarginine and mortality 38. Holdaas H, Fellstrom B, Jardine AG, et al., Assessment of
11. Paoletti E, Bellino D, Cassottana P, et al., Left ventricular in patients with end-stage renal disease: a prospective study, LEscol in Renal Transplantation (ALERT) Study Investigators.
hypertrophy in non-diabetic pre-dialysis CKD, Am J Kidney Dis, Lancet, 2001;358:2113–17. Effect of fluvastatin on cardiac outcomes in renal transplant
2005;46:320–27. 26. Yeun JY, Levine RA, Mantadilok V, Kaysen GA, C-Reactive recipients: a multicentre, randomised, placebo-controlled trial,
12. Valderrabano F, Horl WH, Macdougall IC, et al., PRE-dialysis Protein predicts all-cause and cardiovascular mortality in Lancet, 2003;361:2024–31.
survey on anaemia management, Nephrol Dial Transplant, hemodialysis patients, Am J Kidney Dis, 2000;35:469–76. 39. Heinze G, Mitterbauer C, Regele H, et al., Angiotensin-
2003;18:89–100. 27. Zoccali C, Mallamaci F, Parlongo S, et al., Plasma converting enzyme inhibitor or angiotensin II type 1 receptor
13. Miettinen H, Haffner SM, Lehto S, et al., Proteinuria predicts norepinephrine predicts survival and incident cardiovascular antagonist therapy is associated with prolonged patient and
stroke and other atherosclerotic vascular disease events in events in patients with end-stage renal disease, Circulation, graft survival after renal transplantation, J Am Soc Nephrol,
nondiabetic and non-insulin dependent diabetic subjects, 2002;105:1354–9. 2006;17:889–99.
Stroke, 1996;27:2033–9. 28. Rigatto C, Parfrey P, Therapy Insight: management of 40. Opelz G, Zeier M, Laux G, et al., No improvement of patient
14. Tonelli M, Bohm C, Pandeya S, et al., Cardiac risk factors and cardiovascular disease in the renal transplant recipient, Nat Clin or graft survival in transplant recipients treated with
the use of cardioprotective medications in patients with Pract Nephrol, 2006;2:514–26. angiotensin-converting enzyme inhibitors or angiotensin II
chronic renal insufficiency, Am J Kidney Dis, 2001;37:484–9. 29. Kasiske BL, Chakkera HA, Roel J, Explained and unexplained type 1 receptor blockers: a collaborative transplant study
15. Foley RN, Parfrey PS, Sarnak MJ, Clinical epidemiology of ischemic heart disease risk after transplantation, J Am Soc report, J Am Soc Nephrol, 2006;17:3257–62.
EUROPEAN RENAL DISEASE 2007 51